Vanguard National Trust
SGMO

Vanguard National Trust’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Vanguard National Trust’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-135
Closed -$33 – 820
2026
Q1 		$33 Buy
+135
New +$54 ﹤0.01% 748

Other funds holding SGMO

NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
AIM
Axiom Investment Management New York $150M AUM
FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Vanguard National Trust's SGMO Position: Q2 2026 in Review

Vanguard National Trust sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 135 shares — an estimated $33 sold.

Vanguard National Trust first reported a position in SGMO in Q1 2026 and held it in 1 quarter. The position peaked at $33 in Q1 2026. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

  • Vanguard National Trust reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 135 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $33.
  • Vanguard National Trust first reported a position in SANGAMO THERAPEUTICS INC in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's SANGAMO THERAPEUTICS INC position peaked at $33 in Q1 2026.
  • 6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.